Prevail Gets $75M For Parkinson’s Gene Therapy, Bolstering NY Biotech – Xconomy
Endpoints News |
Prevail Gets $75M For Parkinson's Gene Therapy, Bolstering NY Biotech
Xconomy A potential gene therapy for Parkinson's disease has just gotten a big boost thanks to one of the larger Series A investment rounds in years for a New York biotech. The funding, for Prevail Therapeutics, provides another jolt for the city's life … Prevail grabs $75MA round in the hunt for new gene therapies to stop the destruction caused by Parkinson's Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with … |
